Vedran Miletić

Dr. Vedran Miletić

University of Rijeka Department of Informatics
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Biophysical Journal
Verified
Journal Article
Closed access
AHAna M. Herrera-Rodríguez
Ana M. Herrera-Rodríguez
Vedran MiletićVedran Miletić
Vedran Miletić
CACamilo Aponte-Santamaría
Camilo Aponte-Santamaría
FGFrauke Gräter
Frauke Gräter

11 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Vedran MiletićVedran Miletić
Vedran Miletić
IOIvica Odorčić
Ivica Odorčić
PNPatrik Nikolić
Patrik Nikolić
Željko M SvedružićŽeljko M Svedružić
Željko M Svedružić
We use our earlier experimental studies of the catalytic mechanism of DNA methyltransferases to prepare in silico a family of novel mechanism-based inhibitors of human Dnmt1. Highly specific inhibitors of DNA methylation can be used for analysis of human epigenome and for the creation of iPS cells. We describe a set of adenosyl-1-methyl-pyrimidin-2-one derivatives as novel mechanism-based inhibitors of mammalian DNA methyltransferase Dnmt1. The inhibitors have been designed to bind simultaneously in the active site and the cofactor site and thus act as transition-state analogues. Molecular dynamics studies showed that the lead compound can form between 6 to 9 binding interactions with Dnmt1. QM/MM analysis showed that the upon binding to Dnmt1 the inhibitor can form a covalent adduct with active site Cys1226 and thus act as a mechanism-based suicide-inhibitor. The inhibitor can target DNA-bond and DNA-free form of Dnmt1, however the suicide-inhibition step is more likely to happen when DNA is bound to Dnmt1. The validity of presented analysis is described in detail using 69 modifications in the lead compound structure. In total 18 of the presented 69 modifications can be used to prepare a family of highly specific inhibitors that can differentiate even between closely related enzymes such as Dnmt1 and Dnmt3a DNA methyltransferases. Presented results can be used for preparation of some highly specific and potent inhibitors of mammalian DNA methylation with specific pharmacological properties.

8 April 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Željko M SvedružićŽeljko M Svedružić
Željko M Svedružić
Katarina VrbnjakKatarina Vrbnjak
Katarina Vrbnjak
MMManuel Martinović
Manuel Martinović
Vedran MiletićVedran Miletić
Vedran Miletić
Significance: The majority of the drugs which target membrane-embedded protease γ-secretase show an unusual biphasic activation–inhibition dose-response in cells, model animals, and humans. Semagacestat and avagacestat are two biphasic drugs that can facilitate cognitive decline in patients with Alzheimer’s disease. Initial mechanistic studies showed that the biphasic drugs, and pathogenic mutations, can produce the same type of changes in γ-secretase activity. Results: DAPT, semagacestat LY-411,575, and avagacestat are four drugs that show different binding constants, and a biphasic activation–inhibition dose-response for amyloid-β-40 products in SH-SY5 cells. Multiscale molecular dynamics studies have shown that all four drugs bind to the most mobile parts in the presenilin structure, at different ends of the 29 Å long active site tunnel. The biphasic dose-response assays are a result of the modulation of γ-secretase activity by the concurrent binding of multiple drug molecules at each end of the active site tunnel. The drugs activate γ-secretase by facilitating the opening of the active site tunnel, when the rate-limiting step is the tunnel opening, and the formation of the enzyme–substrate complex. The drugs inhibit γ-secretase as uncompetitive inhibitors by binding next to the substrate, to dynamic enzyme structures which regulate processive catalysis. The drugs can modulate the production of different amyloid-β catalytic intermediates by penetration into the active site tunnel, to different depths, with different flexibility and different binding affinity. Conclusions: Biphasic drugs and pathogenic mutations can affect the same dynamic protein structures that control processive catalysis. Successful drug-design strategies must incorporate transient changes in the γ-secretase structure in the development of specific modulators of its catalytic activity.

Verified
Journal Article
Open access
PDF file
LMLara Saftić Martinović
Lara Saftić Martinović
NBNada Birkic
Nada Birkic
Vedran MiletićVedran Miletić
Vedran Miletić
RARoberto Antolović
Roberto Antolović
Danijela ŠtanfelDanijela Štanfel
Danijela Štanfel
KWKarlo Wittine
Karlo Wittine
The antioxidant activity and chemical stability of 6-amino-6-deoxy-L-ascorbic acid (D1) and N-methyl-6-amino-6-deoxy-L-ascorbic acid (D2) were examined with ABTS and DPPH assays and compared with the reference L-ascorbic acid (AA). In addition, the optimal storing conditions, as well as the pH at which the amino derivatives maintain stability, were determined using mass spectrometry. Comparable antioxidant activities were observed for NH-bioisosteres and AA. Moreover, D1 showed higher stability in an acidic medium than the parent AA. In addition, AA, D1, and D2 share the same docking profile, with wild-type human peroxiredoxin as a model system. Their docking scores are similar to those of dithiothreitol (DTT). This suggests a similar binding affinity to the human peroxiredoxin binding site.

1 October 2012
Verified
Conference Paper
Closed access
Vedran MiletićVedran Miletić
Vedran Miletić
BMBranko Mikac
Branko Mikac
MDMatija Dzanko
Matija Dzanko
The paper describes the design goals and methodology in creating a new model of optical telecommunication network. The model is implemented by discrete-event network simulator ns-3. The advantages of using the existing simulator core infrastructure provided by ns-3 are analyzed and compared to building own simulator from scratch, or selecting a tool among other existing simulators such as ns-2, OMNeT++, and OPNET. The requirements for feature functionality are outlined and high-level overview of the model architecture and its components are provided. Finally, the possibilities for extending the model in future research and development work are described.

1 April 2014
Verified
Conference Paper
Closed access
Vedran MiletićVedran Miletić
Vedran Miletić
DMDimitris Maniadakis
Dimitris Maniadakis
BMBranko Mikac
Branko Mikac
Dimitris VaroutasDimitris Varoutas
Dimitris Varoutas
Network availability is of paramount importance in optical telecommunication networks. Their rising connectivity and consequently their availability is compromised by link and node failures, usually due to physical force (e.g. digging, earthquake or fire). Single link failures can in turn cause multiple failures in case a failure hits a shared risk link group (SRLG), which is a group of logically distinct links sharing a common physical resource, be it a cable or a conduit. The number and length of SRLGs, as well as the characteristics of the underlying physical topology can significantly affect network availability. Especially, the physical topology can be represented by realistic synthetic graphs which are created by numerous geographic graph generators. This work describes the implementation and usage of six different physical topology models (Random Geometric, Gabriel, Relative Neighborhood, K-Nearest Neighbor, Waxman and Spatial Barabási-Albert) for investigation of the influence of the underlying topology on the optical telecommunication network availability. Network availability is estimated using Monte Carlo simulations based on a model of optical telecommunication network implemented by network simulator ns-3. Scenarios utilizing six topology models both in absence and presence of SRLGs are studied, and the optical network availability sensitivity to the underlying physical network topology is presented as the main result.